8-K: Quoin Pharmaceuticals Announces Termination of Contingent Value Rights Related to 2021 Cellect Biotherapeutics Spinoff

Quoin Pharmaceuticals has announced the termination of contingent value rights (CVRs) related to the 2021 sale of Cellect Biotherapeutics, with no financial impact on Quoin.

Summary

• Quoin Pharmaceuticals Ltd. has reported the termination of contingent value rights (CVRs) that were issued in connection with the sale of Cellect Biotherapeutics in 2021.
• These CVRs were granted to pre-merger Cellect shareholders as part of the consideration for the sale of Cellect Biotherapeutics to EnCellX, Inc.
• The CVRs entitled holders to potential payments based on the future performance of the spun-out business, including sales, milestone payments, license fees, and exit fees.
• Quoin Pharmaceuticals was not entitled to any proceeds from these CVRs, and therefore, no asset or liability was recorded on their financial statements.
• The termination of the CVRs was certified by the acting CEO of EnCellX, Inc. on February 29, 2024.

Sentiment

Score: 7

Explanation: The document is neutral in tone, reporting a procedural event with no direct financial impact on the company. The termination of the CVRs was expected and does not indicate any positive or negative change in the company's outlook.

Positives

• The termination of the CVRs has no negative financial impact on Quoin Pharmaceuticals as they were not entitled to any proceeds.

Industry Context

This announcement is specific to the corporate structure and past transactions of Quoin Pharmaceuticals and does not reflect broader industry trends.

Stakeholder Impact

• The termination of the CVRs has no direct impact on Quoin Pharmaceuticals shareholders as the company was not entitled to any proceeds from the CVRs.

Key Dates

Keywords

Contingent Value Rights, CVR, Cellect Biotherapeutics, Quoin Pharmaceuticals, EnCellX, Merger, Share Transfer, Termination